Sensei Biotherapeutics Stock Forecast, Price & News

+0.37 (+2.62 %)
(As of 04/12/2021 12:00 AM ET)
Today's Range
Now: $14.50
50-Day Range
MA: $15.26
52-Week Range
Now: $14.50
Volume37,249 shs
Average Volume240,037 shs
Market Capitalization$443.53 million
P/E RatioN/A
Dividend YieldN/A
Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
Sensei Biotherapeutics logo

Industry, Sector and Symbol

Industry Biotechnology
Current SymbolNASDAQ:SNSE
Phone240 243 8000
Year FoundedN/A



Sales & Book Value

Annual SalesN/A



Market Cap$443.53 million
Next Earnings Date6/24/2021 (Estimated)
OptionableNot Optionable


Sensei Biotherapeutics Inc
February 10, 2021 |
Sensei Biotherapeutics Inc Registered Shs Stock , SNSE
February 6, 2021 |
Sensei Biotherapeutics, Inc. (SNSE)
February 5, 2021 |
See More Headlines


Overall MarketRank

2.03 out of 5 stars

Medical Sector

49th out of 2,016 stocks

Biotechnology Industry

2nd out of 144 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
+0.37 (+2.62 %)
(As of 04/12/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive SNSE News and Ratings via Email

Sign-up to receive the latest news and ratings for SNSE and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Sensei Biotherapeutics (NASDAQ:SNSE) Frequently Asked Questions

Is Sensei Biotherapeutics a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sensei Biotherapeutics in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Sensei Biotherapeutics stock.
View analyst ratings for Sensei Biotherapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Sensei Biotherapeutics?

Wall Street analysts have given Sensei Biotherapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Sensei Biotherapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Sensei Biotherapeutics' next earnings date?

Sensei Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, June 24th 2021.
View our earnings forecast for Sensei Biotherapeutics

What price target have analysts set for SNSE?

4 equities research analysts have issued 1 year target prices for Sensei Biotherapeutics' stock. Their forecasts range from $25.00 to $36.00. On average, they anticipate Sensei Biotherapeutics' share price to reach $29.50 in the next twelve months. This suggests a possible upside of 103.4% from the stock's current price.
View analysts' price targets for Sensei Biotherapeutics
or view top-rated stocks among Wall Street analysts.

Who are Sensei Biotherapeutics' key executives?

Sensei Biotherapeutics' management team includes the following people:
  • Mr. John K. Celebi, Pres, CEO & Director (Age 49, Pay $532.63k)
  • Dr. Robert Hamilton Pierce, Chief Scientific Officer (Age 57, Pay $488.03k)
  • Ms. Anupama Hoey M.B.A., M.S., Chief Bus. Officer (Age 50, Pay $121.65k)
  • Ms. Erin Colgan, Sr. VP of Fin. (Age 40)
  • Dr. Steven A. Fuller, Chief Biopharmaceuticals Devel. Officer
  • Dr. Marie-Louise Fjallskog M.D., Ph.D., Chief Medical Officer (Age 57)

Who are some of Sensei Biotherapeutics' key competitors?

When did Sensei Biotherapeutics IPO?

(SNSE) raised $100 million in an initial public offering on Friday, February 5th 2021. The company issued 5,900,000 shares at $16.00-$18.00 per share. Citigroup, Piper Sandler, Berenberg and Oppenheimer & Co. acted as the underwriters for the IPO.

What is Sensei Biotherapeutics' stock symbol?

Sensei Biotherapeutics trades on the NASDAQ under the ticker symbol "SNSE."

When does the company's lock-up period expire?

Sensei Biotherapeutics' lock-up period expires on Tuesday, August 3rd. Sensei Biotherapeutics had issued 7,000,052 shares in its public offering on February 4th. The total size of the offering was $133,000,988 based on an initial share price of $19.00. After the expiration of the company's lock-up period, company insiders and major shareholders will be able to sell their shares of the company.

How do I buy shares of Sensei Biotherapeutics?

Shares of SNSE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sensei Biotherapeutics' stock price today?

One share of SNSE stock can currently be purchased for approximately $14.50.

How much money does Sensei Biotherapeutics make?

Sensei Biotherapeutics has a market capitalization of $443.53 million.

What is Sensei Biotherapeutics' official website?

The official website for Sensei Biotherapeutics is

How can I contact Sensei Biotherapeutics?

The company can be reached via phone at 240 243 8000.

This page was last updated on 4/12/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.